Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

1期进行中（已停止招募） NCT04477200

适应症	Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma
分期	1期
申办方	University of Michigan Rogel Cancer Center
状态	进行中（已停止招募）
受试者人数	68 人
干预（药物）	Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide, Mycophenolate Mofetil
开始日期	2020年8月5日
完成日期	2025年1月6日
结果公布日	2026年5月14日

摘要

This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.

Concentration of Mycophenolic Acid (MPA) in Tumor Tissue in Phase 0 Participants

At 1 week · nmol/g

Phase 0 - Recurrent Glioblastoma (GBM) / Gliosarcoma (GS) - Level 2	1.87 nmol/g
Phase 0 - Recurrent Glioblastoma (GBM) / Gliosarcoma (GS) - Level 3	2.65 nmol/g
Phase 0 - Recurrent Glioblastoma (GBM) / Gliosarcoma (GS) - Level 4	2.65 nmol/g
Phase 0 - Recurrent Glioblastoma (GBM) / Gliosarcoma (GS) - Level 5	1.8 nmol/g
Phase 0 - Recurrent Glioblastoma (GBM) / Gliosarcoma (GS) - Level 2	1.11 nmol/g
Phase 0 - Recurrent Glioblastoma (GBM) / Gliosarcoma (GS) - Level 3	0.81 nmol/g

Number of Recurrent Phase 1 Participants Who Experience Dose-limiting Toxicities (DLTs) at Each Dose Level

Up to 28 days following completion of MMF + RT (up to ~9 weeks) · number of patients reporting a DLT

Phase 1 - Recurrent GBM / GS - Level 3	0 number of patients reporting a DLT
Phase 1 - Recurrent GBM / GS - Level 4	0 number of patients reporting a DLT
Phase 1 - Recurrent GBM / GS - Level 5	0 number of patients reporting a DLT

Number of Newly Diagnosed Phase 1 Participants Who Experience Dose-limiting Toxicities (DLTs) at Each Dose Level -- DLT1 Period

Up to 28 days following completion of MMF + RT + TMZ (up to ~11 weeks) · number of patients reporting a DLT

Phase 1 - Newly Diagnosed GBM / GS - Level 3	0 number of patients reporting a DLT
Phase 1 - Newly Diagnosed GBM / GS- Level 4	0 number of patients reporting a DLT
Phase 1 - Newly Diagnosed GBM / GS- Level 5	5 number of patients reporting a DLT

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский